23andMe Holding Co. is a biotechnology company that specializes in personal genomics and biotechnology research
It offers direct-to-consumer genetic testing services, allowing individuals to explore their ancestry, health risks, and genetic traits through easy-to-use saliva collection kits. The company aims to empower people with insights into their genetic information and provide valuable resources for health-related decision-making. Additionally, 23andMe is involved in pharmaceutical research, leveraging its vast genetic database to facilitate drug discovery and development through collaborations with various biopharmaceutical companies.
Tariffs on metal imports create opportunities in ETFs focused on U.S. steelmakers. Top picks are VanEck Steel, SPDR S&P Metals & Mining, and Global X U.S. Infrastructure Development ETF.
23andMe restructures, cutting 40% of its workforce and ending its therapeutic programs to save $35 million annually while exploring strategic alternatives.
Lawyer raises objections to 23andMe's proposed $30 million settlement, arguing it undermines arbitration rights for 5,000 customers following a data breach. The court is set to review the case in late October.
